LBA2 Tumour response analyses by RECIST v1.1 and mRECIST in the phase III EMERALD-3 study of tremelimumab plus durvalumab with or without lenvatinib plus transarterial chemoembolisation (TACE) in embolisation-eligible hepatocellular carcinoma (eeHCC)
作者
J.P. Erinjeri,Z. Ren,Ghassan K. Abou‐Alfa,J. Heo,Riccardo Antonio Lencioni,Y. Arai,Mohamed Bouattour,M.A. Gonzalez Carmona,Y. Guo,Aibing Xu,G.V. Alves,A. Dechaphunkul,G.F. Ho,L. Yueh Ni,H.-T. Hu,Sri Harsha Tekumalla,V. Dave,X. Monzonís,Masatochi Kudo,J. Fan
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
null
坚强冰枫
学术雷锋
北白川anko
吃葡萄不吐葡萄皮
飘逸的大雁
Criminology34
aaaa
散逸层梦游
乐空思
秋风
OK
Elsevier大王
HuiLang
123
v0id
贪玩的秋柔
Julian
Chinlu_Lee
皖公网安备34019202002308
